Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female 55 to 80 years of age at screening~2. The subject has been newly diagnosed as essential hypertension or not treated in the past 2 weeks. If the subject took medication in the past 2 weeks, a wash-out period of at least 2 weeks will be completed prior to performing screening (week -2) assessments~3. The subject has a mean seated SBP at screening visit ≥ 140mmHg (as measured by a mercury sphygmomanometer)~4. Isolated systolic hypertension (ISH) patient (SBP≥ 140mmHg, DBP ≤90mmHg)~5. If the subject is a female of child-bearing potential, she agrees to practice acceptable contraceptive measures during the study, and for 30 days after the last dose of study medication is taken~6. The subject has given written informed consent~Exclusion Criteria:~* A subject will not be eligible for inclusion in this study if any of the following criteria apply :~  1. Mean seated SBP of \> 180 mmHg at screening and during the study~ 2. Known or suspected secondary hypertension~ 3. The subject has anemia defined by hemoglobin concentration \< 10.0 g/dL for male or female~ 4. The subject has a hemoglobinopathy or peripheral vascular disease~ 5. The subject has presence of clinically significant renal or hepatic disease (i.e., subjects with serum creatinine \> 1.4 mg/dL;ALT, AST, total bilirubin, or alkaline phosphatase \> 2.5 times the upper limit of the normal (ULN) reference range~ 6. The subject has presence of unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring pharmacologic treatment~ 7. The subject has a chronic disease requiring intermittent or chronic treatment with oral, intravenous, or intra-articular corticosteroids (i.e., only use of topical, inhaled or nasal corticosteroids is permissible)~ 8. The subject has a clinically significant abnormality identified at screening which in the judgement of the investigator makes the subject unsuitable for inclusion in the study (e.g. physical examination, or electrocardiogram etc.)~ 9. Past medical history or concomitant disease of metabolic acidosis or diabetic ketoacidosis~ 10. The subject has a diagnosis of cancer (other than squamous or basal cell) in the past 3 years and is currently receiving treatment for the active cancer~ 11. Subject who is taking medication known to affect blood pressure~ 12. Known drug or alcohol dependency within 6 months prior to screening as determined by the investigator~ 13. Has taken part in a clinical trial using a marketed product, investigational drug or device within 1 month prior to screening.~ 14. Hypersensitivity to any component of lacidipine and amlodipine

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete